|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2008-4-16
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Coronary artery bypass graft (CABG) surgery is frequently performed and effective; however, perioperative complications related to ischemia-reperfusion injury, including myocardial infarction (MI), remain common and result in significant morbidity and mortality. MC-1, a naturally occurring pyridoxine metabolite and purinergic receptor antagonist, prevents cellular calcium overload and may reduce ischemia-reperfusion injury. Phase 2 trial data suggest that MC-1 may reduce death or MI in high-risk patients undergoing CABG surgery.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1538-3598
|
|
pubmed:author |
pubmed-author:AlexanderJohn HJH,
pubmed-author:Bennett-GuerreroElliottE,
pubmed-author:CarrierMichelM,
pubmed-author:CoteRobertR,
pubmed-author:EllisStephen JSJ,
pubmed-author:EmeryRobert WRWJr,
pubmed-author:HarringtonRobert ARA,
pubmed-author:HasselbladVicV,
pubmed-author:KhalilAhmadA,
pubmed-author:MEND-CABG II Investigators,
pubmed-author:MackMichael JMJ,
pubmed-author:MehtaRajendra HRH,
pubmed-author:MenaschePhilippeP,
pubmed-author:SchulerGerhardG,
pubmed-author:TardifJean-ClaudeJC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
16
|
|
pubmed:volume |
299
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1777-87
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18381567-Aged,
pubmed-meshheading:18381567-Calcium Channel Blockers,
pubmed-meshheading:18381567-Cardiopulmonary Bypass,
pubmed-meshheading:18381567-Coronary Artery Bypass,
pubmed-meshheading:18381567-Double-Blind Method,
pubmed-meshheading:18381567-Female,
pubmed-meshheading:18381567-Humans,
pubmed-meshheading:18381567-Male,
pubmed-meshheading:18381567-Middle Aged,
pubmed-meshheading:18381567-Myocardial Infarction,
pubmed-meshheading:18381567-Myocardial Reperfusion Injury,
pubmed-meshheading:18381567-Purinergic P2 Receptor Antagonists,
pubmed-meshheading:18381567-Pyridoxal Phosphate,
pubmed-meshheading:18381567-Risk
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
|
|
pubmed:affiliation |
Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27715 , USA. john.h.alexander@duke.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
